Cancer Biomarkers Market Size, Share, Trends, Growth Outlook

Cancer Biomarkers Market is estimated to increase at a Compounded Annual Growth Rate of 15.1% CAGR over the forecast period from 2024 to 2030

The Cancer Biomarkers Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Biomarker (Protein Biomarkers, Genetic Biomarkers, Others), By Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer, Others), By Profiling Technologies (Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics), By Application (Diagnostics, Research & Development, Prognostics, Risk Assessment, Others).

An Introduction to Cancer Biomarkers Market in 2024

Cancer biomarkers are molecular indicators found in blood, tissue, or other bodily fluids that are associated with the presence, progression, or treatment response of cancer. In 2024, cancer biomarkers play a critical role in cancer diagnosis, prognosis, and treatment decision-making, enabling clinicians to detect cancer at earlier stages, predict disease outcomes, and tailor therapies to individual patients. Biomarkers may include genetic mutations, protein markers, circulating tumor cells, or microRNA signatures, which can be detected using various laboratory techniques such as DNA sequencing, immunohistochemistry, or liquid biopsy assays. By providing valuable information about tumor biology, aggressiveness, and drug sensitivity, cancer biomarkers guide personalized treatment strategies, monitor treatment response, and identify potential therapeutic targets for precision medicine approaches. With ongoing research efforts focused on identifying novel biomarkers and developing innovative diagnostic technologies, cancer biomarkers continue to revolutionize cancer care, offering new opportunities for early detection, targeted therapy, and improved outcomes for patients with cancer.

Market Trend: Advancements in Biomarker Discovery Technologies

One prominent trend in the cancer biomarkers market is the advancements in biomarker discovery technologies. With the advent of high-throughput omics technologies, such as genomics, proteomics, and metabolomics, researchers have gained deeper insights into the molecular mechanisms underlying cancer development and progression. These technologies enable the identification and characterization of novel biomarkers, including genetic mutations, protein expression patterns, and metabolic signatures, associated with various cancer types. Additionally, the integration of bioinformatics tools and artificial intelligence algorithms enhances data analysis and interpretation, facilitating the discovery of clinically relevant biomarkers with diagnostic, prognostic, and predictive value. The continuous evolution of biomarker discovery technologies drives innovation in cancer diagnostics and personalized medicine, offering new opportunities for the development of targeted therapies and precision oncology approaches.

Market Driver: Rising Incidence and Mortality of Cancer Globally

A significant driver in the cancer biomarkers market is the rising incidence and mortality of cancer globally. Cancer remains a leading cause of morbidity and mortality worldwide, with millions of new cases diagnosed each year and a significant burden on healthcare systems. Early detection and accurate diagnosis are critical for improving cancer outcomes and reducing mortality rates. Biomarkers play a crucial role in cancer detection, screening, and monitoring by providing non-invasive and sensitive indicators of disease presence, progression, and response to therapy. The increasing prevalence of cancer underscores the urgent need for effective biomarkers that can aid in early detection, risk stratification, treatment selection, and surveillance, driving the demand for innovative biomarker-based diagnostic tests and companion diagnostics. As the incidence of cancer continues to rise, there is a growing opportunity to leverage biomarkers for precision oncology and personalized cancer care, ultimately improving patient outcomes and survival rates.

Market Opportunity: Development of Liquid Biopsy Biomarker Assays

An emerging opportunity in the cancer biomarkers market is the development of liquid biopsy biomarker assays. Liquid biopsy refers to the non-invasive sampling and analysis of biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and microRNAs, from biofluids such as blood, urine, and saliva. Liquid biopsy assays offer several advantages over traditional tissue biopsy, including real-time monitoring of disease progression, assessment of treatment response, and detection of minimal residual disease and treatment resistance. Furthermore, liquid biopsy enables the identification of biomarkers that may not be accessible through tissue biopsy, providing a comprehensive view of tumor heterogeneity and evolution. The development of highly sensitive and specific liquid biopsy assays for detecting and monitoring cancer biomarkers presents a significant opportunity for diagnostic companies and research organizations to innovate and commercialize new products for cancer detection, monitoring, and management. By leveraging liquid biopsy technologies, stakeholders can address unmet clinical needs in cancer diagnosis and surveillance, revolutionizing the way cancer is detected, monitored, and treated.

Cancer Biomarkers Market Share Analysis: Protein Biomarkers for Breast Cancer is the fastest growing segment over the forecast period to 2030

Among the segments in the Cancer Biomarkers Market, the Protein Biomarkers for Breast Cancer segment is experiencing the fastest growth. This growth can be attributed to several factors driving the demand for protein biomarkers in breast cancer diagnosis, prognosis, and treatment. Protein biomarkers, such as hormone receptors (estrogen receptor, progesterone receptor) and human epidermal growth factor receptor 2 (HER2), play a crucial role in identifying breast cancer subtypes, predicting treatment response, and guiding personalized treatment decisions. The increasing incidence of breast cancer worldwide and the growing emphasis on early detection and precision medicine fuel the demand for protein biomarker-based diagnostics and prognostics. Furthermore, advancements in proteomics technologies, such as mass spectrometry and protein microarrays, enable the identification and validation of novel protein biomarkers associated with breast cancer development and progression. Additionally, the integration of protein biomarkers into multiplex assays and companion diagnostics enhances their clinical utility and adoption in routine clinical practice. As healthcare providers prioritize targeted therapies and personalized medicine approaches in breast cancer management, the Protein Biomarkers for Breast Cancer segment is expected to sustain its rapid growth in the Cancer Biomarkers Market.

Cancer Biomarkers Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, Agilent Technologies Inc, Becton, Dickinson and Company, bioMérieux S.A., Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Illumina Inc, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc

Cancer Biomarkers Market Segmentation

By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Cancer Biomarkers Market Companies

Abbott Laboratories
Agilent Technologies Inc
Becton, Dickinson and Company
bioMérieux S.A.
Bio-Rad Laboratories Inc
F. Hoffmann-La Roche Ltd
Illumina Inc
Merck KGaA
QIAGEN N.V.
Thermo Fisher Scientific Inc

Reasons to Buy the Cancer Biomarkers Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cancer Biomarkers Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cancer Biomarkers Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Cancer Biomarkers Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cancer Biomarkers Market Size Outlook, $ Million, 2021 to 2030
3.2 Cancer Biomarkers Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cancer Biomarkers Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cancer Biomarkers Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cancer Biomarkers Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cancer Biomarkers Industry
4.2 Key Market Trends in Cancer Biomarkers Industry
4.3 Potential Opportunities in Cancer Biomarkers Industry
4.4 Key Challenges in Cancer Biomarkers Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cancer Biomarkers Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cancer Biomarkers Market Outlook by Segments
7.1 Cancer Biomarkers Market Outlook by Segments, $ Million, 2021- 2030
By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others

8 North America Cancer Biomarkers Market Analysis and Outlook To 2030
8.1 Introduction to North America Cancer Biomarkers Markets in 2024
8.2 North America Cancer Biomarkers Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cancer Biomarkers Market size Outlook by Segments, 2021-2030
By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others

9 Europe Cancer Biomarkers Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cancer Biomarkers Markets in 2024
9.2 Europe Cancer Biomarkers Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cancer Biomarkers Market Size Outlook by Segments, 2021-2030
By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others

10 Asia Pacific Cancer Biomarkers Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cancer Biomarkers Markets in 2024
10.2 Asia Pacific Cancer Biomarkers Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cancer Biomarkers Market size Outlook by Segments, 2021-2030
By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others

11 South America Cancer Biomarkers Market Analysis and Outlook To 2030
11.1 Introduction to South America Cancer Biomarkers Markets in 2024
11.2 South America Cancer Biomarkers Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cancer Biomarkers Market size Outlook by Segments, 2021-2030
By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others
12 Middle East and Africa Cancer Biomarkers Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cancer Biomarkers Markets in 2024
12.2 Middle East and Africa Cancer Biomarkers Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cancer Biomarkers Market size Outlook by Segments, 2021-2030
By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Agilent Technologies Inc
Becton, Dickinson and Company
bioMérieux S.A.
Bio-Rad Laboratories Inc
F. Hoffmann-La Roche Ltd
Illumina Inc
Merck KGaA
QIAGEN N.V.
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Biomarker
Protein Biomarkers
Genetic Biomarkers
Others
By Cancer
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Leukemia
Thyroid Cancer
Bladder Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Others
By Profiling Technologies
Omics Technologies
Imaging Technologies
Immunoassay
Bioinformatics
Cytogenetics
By Application
Diagnostics
Research & Development
Prognostics
Risk Assessment
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)